<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04836689</url>
  </required_header>
  <id_info>
    <org_study_id>RMB-0490-20</org_study_id>
    <nct_id>NCT04836689</nct_id>
  </id_info>
  <brief_title>Influence of Respiratory Rate Settings on CO2 Levels During Nasal Intermittent Positive Pressure Ventilation (NIPPV).</brief_title>
  <official_title>Influence of Respiratory Rate Settings on CO2 Levels During Nasal Intermittent Positive Pressure Ventilation (NIPPV).</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Rambam Health Care Campus</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Rambam Health Care Campus</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Infants will be monitored by TcCO2 during three consecutive time periods of one hour each on&#xD;
      a high and low rate of NIPPV, when in a stable condition. NIPPV rate will start high/low,&#xD;
      changed to low/high and switched back to starting rate.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This will be a prospective, crossover observational study that will be performed at Rambam&#xD;
      NICU.&#xD;
&#xD;
      Infants will be monitored by TcCO2 during three consecutive time periods of one hour each on&#xD;
      a high and low rate of NIPPV, when in a stable condition.&#xD;
&#xD;
      NIPPV rate will start high/low, changed to low/high and switched back to starting rate.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">April 1, 2021</start_date>
  <completion_date type="Anticipated">April 1, 2023</completion_date>
  <primary_completion_date type="Anticipated">April 1, 2023</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <intervention_model_description>Infants will be monitored by TcCO2 during three consecutive time periods of one hour each on a high and low rate of NIPPV, when in a stable condition. NIPPV rate will start high/low, changed to low/high and switched back to starting rate</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Trans cutaneous CO2 (TCCO2)</measure>
    <time_frame>During the 3 hours of the study</time_frame>
    <description>Trans cutaneous CO2</description>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">50</enrollment>
  <condition>Ventilator Lung; Newborn</condition>
  <arm_group>
    <arm_group_label>30 breaths per minutes</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>Using NIPPV with rate of 30 for 1 hour. Measuring trans cutaneous CO2</description>
  </arm_group>
  <arm_group>
    <arm_group_label>10 breaths per minute</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>Using NIPPV with rate of 10 for 1 hour. Measuring trans cutaneous CO2</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>nasal intermittent positive pressure ventilation (NIPPV).</intervention_name>
    <description>NIPPV will be administered using Leoni (Heinen&amp;Löwenstein, Bad Ems, Germany) and RAM cannula (Neotech, Valencia, CA).&#xD;
After initial setting and before routine blood gas testing, tcCO2 will be connected and calibrated. We will use SenTec digital monitor (SenTec AG, Therwil, Switzerland). Correlation/agreement between the tcCO2 and PCO2 will be assessed and documented in each infant.&#xD;
For Each infant we will get 2 set of data: Change in measurements when changing from 30 bpm to 10 bpm, and change in measurements when changing from 10 bpm to 30 bpm At the end of each hour, before rate change, we will document the following measurements:TcCO2, FiO2, saturation, the infant's respiratory rate (as measured in the monitor), number of apneas, bradycardia (heart rate&lt;100 bpm), saturation&lt;90% and&gt;94% episodes (as measured in the monitor), 1-hour saturation histogram clasification.</description>
    <arm_group_label>10 breaths per minute</arm_group_label>
    <arm_group_label>30 breaths per minutes</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Gestational age 240 to 336.&#xD;
&#xD;
          -  At least 6 hours of stabilized NIPPV settings, i.e. minor changes in settings (FiO2&#xD;
             ≤0.10, PIP≤ 2.0 cmH2O, RR≤ 5 brm).&#xD;
&#xD;
          -  At least 6 hours of stabilized tcCO2, i.e. ≤5 mmHg variation.&#xD;
&#xD;
          -  At least 6 hours from surfactant administration.&#xD;
&#xD;
          -  Parental consent&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  If NIPPV set rate is 10 bpm and tcCO2 related pCO2 is&lt;40mmHg.&#xD;
&#xD;
          -  If NIPPV set rate is 30 bpm and tcCO2 related pCO2 is&gt;60mmHg.&#xD;
&#xD;
          -  Unstable infants due to acute conditions (sepsis. IVH), or congenital malformations.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>1 Month</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Ori Hochwald, MD</last_name>
    <phone>97247774111</phone>
    <email>O_hochwald@RMC.gov.il</email>
  </overall_contact>
  <location>
    <facility>
      <name>Rambam Medical Center</name>
      <address>
        <city>Haifa</city>
        <zip>31096</zip>
        <country>Israel</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Ori Hochwald, MD</last_name>
      <phone>972-4-7774111</phone>
      <email>o_hochwald@rambam.health.gov.il</email>
    </contact>
  </location>
  <location_countries>
    <country>Israel</country>
  </location_countries>
  <verification_date>April 2021</verification_date>
  <study_first_submitted>April 6, 2021</study_first_submitted>
  <study_first_submitted_qc>April 7, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">April 8, 2021</study_first_posted>
  <last_update_submitted>April 7, 2021</last_update_submitted>
  <last_update_submitted_qc>April 7, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">April 12, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Rambam Health Care Campus</investigator_affiliation>
    <investigator_full_name>Ori Hochwald , MD</investigator_full_name>
    <investigator_title>Director, NICU</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Bronchopulmonary Dysplasia</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

